Celltrion, Inc. Logo

Celltrion, Inc.

A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.

068270 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
인천광역시 연수구 아카데미로 23, 인천광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Celltrion, Inc. is a leading global biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of innovative therapeutics. A pioneer in the biosimilar field, Celltrion launched the world's first monoclonal antibody biosimilar and continues to be a market leader. The company's portfolio includes a range of biosimilars and novel drugs targeting therapeutic areas such as immunology, oncology, hematology, and endocrinology. Celltrion provides comprehensive, end-to-end solutions across the biopharmaceutical value chain, from R&D and clinical trials to production and sales, with a commitment to improving worldwide patient access to high-quality, affordable medicines.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Celltrion, Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 724.1 KB
2025-09-17 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득결정)
Korean 33.3 KB
2025-09-08 00:00
Related Party Transaction
임원ㆍ주요주주특정증권등거래계획보고서
Korean 70.7 KB
2025-09-05 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.0 KB
2025-09-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.5 KB
2025-09-01 00:00
Legal Proceedings Report
투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 유럽 임상 3상 시험계획 승인(Part2))
Korean 12.2 KB
2025-09-01 00:00
Major Shareholding Notification
대규모기업집단현황공시[분기별공시(개별회사용)]
Korean 31.0 KB
2025-08-27 00:00
Regulatory News Service
풍문또는보도에대한해명(미확정)
Korean 7.9 KB
2025-08-25 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.5 KB
2025-08-19 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 747.4 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 5.6 MB
2025-08-14 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.5 KB

Automate Your Workflow. Get a real-time feed of all Celltrion, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Celltrion, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Novartis AG Logo
Develops and markets innovative medicines globally using advanced science and technology.
Switzerland NOVN
Develops first-in-class drugs and supplements for metabolic and fibrotic diseases.
South Korea 229500
Novo Nordisk Logo
Develops medicines and devices for chronic diseases like diabetes, obesity, and rare disorders.
Denmark NOVO
NUFORMIX PLC Logo
Repurposing drugs for fibrosis and oncology using proprietary cocrystal technology.
United Kingdom NFX
NUTEX Investments Plc Logo
Develops & distributes health, cosmetic & pharma products from natural ingredients globally.
Hungary NUTEX
Nxera Pharma Co., Ltd. Logo
Biopharma using SBDD tech to develop medicines for neurology and gastroenterology.
Japan 4565
ObsEva SA Logo
Developed novel therapeutics for women's reproductive health and pregnancy.
Switzerland OBSN
ODI Pharma AB Logo
Distributes pharmaceutical medicinal cannabis products across Eastern Europe, with a focus on Poland.
Sweden ODI
OliX Pharmaceuticals, Inc. Logo
Developing RNAi therapeutics for dermatology, ophthalmology, and metabolic diseases via an asiRNA platform.
South Korea 226950
ONCODESIGN Logo
Developing precision oncology solutions for resistant and metastatic cancers.
France ALONC

Talk to a Data Expert

Have a question? We'll get back to you promptly.